MAPK3 and neoplasm: Growth inhibition achieved with high doses of PD 0325901 was accompanied by a decrease in ERK1/2 phosphorylation, which was maintained even when lower doses of 1.5–3 mg/kg PD 0325901 were used; however, these lower doses were only able to cause a modest tumour growth delay [6], [10], [11], [12].